Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors improve cardiovascular, kidney, and metabolic outcomes.
- Access to glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors is not equitable across different populations.
- Disparities in the use of these medications could affect health outcomes related to cardiovascular, kidney, and metabolic conditions.
- An Equity-First Framework is proposed to address these disparities and promote pharmacoequity in cardiovascular-kidney-metabolic care.
Simplified